# Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

> **NCT00331175** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (—)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Peptide YY3-36

## Key facts

- **NCT ID:** NCT00331175
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 31 (—)
- **Last updated:** 2006-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331175, "Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00331175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*